Surgical complications and survival after pelvic exenteration: our experience following 60 procedures

Purpose of Investigation: Analyse the results of pelvic exenteration for pelvic malignancies in a tertiary referral center. Materials and methods: Between 2011 and 2018, 60 patients underwent a pelvic exenteration. The indications were cervical (44 patients), vaginal (4), recurrent ovarian (6), endometrial (2), vulval (2), recurrent sigmoid colon (1), and bladder cancer (1). Results: Out of the 60 exenterations, 31 were total, 21 anterior, and 8 posterior. A Bricker non-continent ileal or sigmoid urinary conduit was performed in 51 out of 52 anterior and total exenterations. Early complications occurred in 34 patients of whom four perioperative deaths (6.6 %). Among the 60 patients, at this moment, 33 are alive, 25 are dead, and two are lost to follow-up. Conclusion: Pelvic exenteration for recurrent or advanced pelvic malignancies can be associated with long-term survival and even cure without high perioperative mortality in properly selected patients. However, postoperative complications can be lethal.

Complications; Pelvic exenteration; Survival.

[1] Brunschwig A.: “Complete excision of pelvic viscera for advanced carcinoma: a one-stage abdominoperineal operation with end colostomy and bilateral ureteral implantation into the colon above the colostomy”. Cancer, 1948, 1, 177.

[2] Graves S., Seagle B.L., Strohl A.E., Shahabi S., Nieves-Neira W.: “Survival after pelvic exenteration for cervical cancer: A National Cancer Database Study”. Int. J. Gynecol. Cancer, 2017, 27, 1610.

[3] Saunders N.: “Pelvic exenteration: by whom and for whom?” Lancet, 1995, 345, 5.

[4] Schmidt A.M., Imesch P., Fink D., Egger H.: “Pelvic exenterations for advanced and recurrent endometrial cancer: clinical outcomes of 40 patients”. Int. J. Gynecol. Cancer, 2016, 26, 716.

[5] Khoury-Collado F., Einstein M.H., Bochner B.H., Alektiar K.M., Sonoda Y., Abu-Rustum N.R., et al.: “Pelvic exenteration with curative intent for recurrent uterine malignancies”. Gynecol. Oncol., 2012, 124, 42.

[6] Fotopoulou C., Neumann U., Kraetschell R., Schefold J.C., Weidemann H., Lichtenegger W., Sehouli J.: “Long-term clinical outcome of pelvic exenteration in patients with advanced gynecological malignancies”. J. Surg. Oncol., 2010, 101, 507.

[7] Chiantera V., Rossi M., De Iaco P., Koehler C., Marnitz S., Gallotta V., et al.: “Morbidity after pelvic exenteration for gynecological malignancies: a retrospective multicentric study of 230 patients”. Int. J. Gynecol. Cancer, 2014, 24, 156.

[8] Houvenaeghel G., Moutardier V., Karsenty G., Bladou F., Lelong B., Buttarelli M., Delpero J.R.: “Major complications of urinary diversion after pelvic exenteration for gynecologic malignancies: a 23- year mono-institutional experience in 124 patients”. Gynecol. Oncol., 2004, 92, 680.

[9] Berek J.S., Howe C., Lagasse L.D., Hacker N.F.: “Pelvic exenteration for recurrent gynecologic malignancy: survival and morbidity analysis of the 45-year experience at UCLA”. Gynecol. Oncol., 2005, 99, 153.

[10] Sharma S., Odunsi K., Driscoll D., Lele S.: “Pelvic exenteration for gynecological malignancies: twenty-year experience at Rosewell Park Cancer Institute”. Int. J. Gynecol. Cancer, 2005, 15, 475.

[11] Park J.Y., Choi H.J., Jeong S.Y., Park J.Y., Choi H.J., Jeong S.Y.: “The role of pelvic exenteration and reconstruction for treatment of advanced or recurrent gynecologic malignancies: analysis of risk factors predicting recurrence and survival”. J. Surg. Oncol., 2007, 96, 560.

[12] Caceres A., Mourton S.M., Bochner B.H., Gerst S.R., Liu L., Alektiar K.M., et al.: “Extended pelvic resections for recurrent uterine and cervical cancer: out-of-the-box surgery”. Int. J. Gynecol., 2008, 18, 1139.

[13] Maggioni A., Roviglione G., Landoni F., Zanagnolo V., Peiretti M., Colombo N., et al.: “Pelvic exenteration: ten-year experience at the European Institute of Oncology in Milan”. Gynecol. Oncol., 2009, 114, 64.

[14] Schmidt A.M., Imesch P., Fink D., Egger H.: “Indications and longterm clinical outcomes in 282 patients with pelvic exenteration foradvanced or recurrent cervical cancer”. Gynecol. Oncol., 2012, 125, 604.

[15] McLean K.A., Zhang W., Dunsmoor-Su R.F., Shah C.A., Gray H.J., Swensen R.E., Goff B.A.: “Pelvic exenteration in the age of modern chemoradiation”. Gynecol. Oncol., 2011, 121, 131.

[16] Baiocchi G., Guimaraes G.C., Rosa Oliveira R.A., Kumagai L.Y., Faloppa C.C., Aguiar S., et al.: “Prognostic factors in pelvic exenteration for gynecological malignancies”. Eur. J. Cancer Surg., 2012, 38, 948.

[17] Jager L., Nilsson P.J., Floter Radestad A.: “Pelvic Exenteration for Recurrent Gynecologic Malignancy. A Study of 28 Consecutive Patients at a Single Institution”. Int. J. Gynecol. Cancer, 2013, 23, 755.

[18] Ungar L., Palfalvi L., Novak Z.: “Primary pelvic exenteration in cervical cancer patients”. Gynecol. Oncol., 2008, 111, S9.

[19] Magrina J.F., Stanhope C.R., Waever A.L.: “Pelvic exenterations: supralevator, infralevator, and with vulvectomy”. Gynecol. Oncol., 1997, 64, 13.

[20] Chiva L.M., Lapuente F., González-Cortijo L.: “Surgical treatment of recurrent cervical cancer: State of the art and new achievements”. Gynecol. Oncol., 2008, 110, S60.

[21] Bricker E.M.: “Bladder substitution for pelvic evisceration”. Surg. Clin. North Am., 1950, 30, 1511.

[22] Ungar L., Palfalvi L.: “Pelvic exenteration without external urinary or fecal diversion in gynecological cancer patients”. Int. J. Gynecol. Cancer, 2006, 16, 364.

[23] Ungar L., Palfalvi L.: “Surgical treatment of lymph node metastases in stage IB cervical cancer: The laterally extended parametrectomy (LEP) procedure”. Int. J. Gynecol. Cancer, 2003, 13, 647.

[24] Palfalvi L., Ungar L.: “Laterally extended parametrectomy (LEP), the technique for radical pelvic side wall dissection: Feasibility, technique and results”. Int. J. Gynecol. Cancer, 2003, 13, 914.

[25] Dindo D., Demartines N., Clavien P.A.: “Classification of surgical complications. A new proposal with evaluation in a cohort of 6336 patients and results of a survey”. Ann. Surg., 2004, 240, 205.

[26] Höckel M., Dornhofer N.: “Review: Pelvic exenteration for gynaecological tumours: achievements and unanswered questions”. Lancet Oncol., 2006, 7, 837.

[27] Friedlander M., Grogan M.: “Guidelines for the treatment of recurrent and metastatic cervical cancer”. Oncologist, 2002, 7, 342.

[28] Höckel M.: “Laterally extended endopelvic resection. Novel surgical treatment of locally recurrent cervical carcinoma involving the pelvic side wall”. Gynecol. Oncol., 2003, 91, 369.

[29] Höckel M., Wolf B., Hentschel B., Horn L.C.: “Surgical treatment and histopathological assessment of advanced cervicovaginal carcinoma: A prospective study and retrospective analysis”. Eur. J. Cancer, 2017, 70, 99.

[30] Căpîlna M.E., Moldovan B., Szabo B.: “Pelvic exenteration - our initial experience in 15 cases”. Eur. J. Gynaecol. Oncol., 2015, 36, 142.

[31] Dessole M., Petrillo M., Lucidi A., Naldini A., Rossi M., De Iaco P., et al.: “Quality of Life in Women After Pelvic Exenteration for Gynecological Malignancies: A Multicentric Study”. Int. J. Gynecol. Cancer, 2018, 28, 267.

[32] de Wilt J.H., van Leeuwen D.H., Logmans A., Verhoef C., Kirkels W.J., Vermaas M., Ansink A.C.: “Pelvic exenteration for primary and recurrent gynecological malignancies”. Eur. J. Obstet. Gynecol. Reprod. Biol., 2007, 134, 243.